NEW
HAVEN, Conn., June 7, 2022
/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a
clinical-stage biopharmaceutical company developing an
investigational therapy Haduvio™ (nalbuphine ER) for pruritus
in prurigo nodularis (PN) and chronic cough in idiopathic pulmonary
fibrosis (IPF), today announced that Jennifer Good, President and CEO, will deliver a
company presentation at 2022 BIO International Convention. In
addition, Ms. Good will be participating in partnership meetings
throughout the conference alongside Farrell Simon, SVP, Head of
Commercial and Strategy. The 2022 BIO International Convention will
be held in person from June 13-16,
2022 in San Diego, CA.
Trevi's President and CEO, Jennifer Good, will present at the BIO
International Convention on June 13
at 4 pm PT
BIO International Convention and Presentation
Details
Date: June 13-16,
2022
Presentation Time: June
13th at 4:00 PM
PT
Presentation Room: Theater 1
Location: San Diego Convention
Center, San Diego, CA
The BIO International Convention attracts 15,000+ biotechnology
and pharma leaders for one week of intensive networking to discover
new opportunities and promising partnerships. The event brings
together a wide spectrum of life science and application
innovators, including drug discovery, biomanufacturing, genomics,
nanotechnology, and cell therapy.
To register for the event, please click here.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development and commercialization of the
investigational therapy Haduvio to treat serious neurologically
mediated conditions. Trevi is conducting a
Phase 2b/3 clinical trial of Haduvio for the treatment of
chronic pruritus associated with prurigo nodularis (PN) and a Phase
2 trial for chronic cough in adults with idiopathic pulmonary
fibrosis (IPF). These conditions share a common pathophysiology
that is mediated through opioid receptors in the central and
peripheral nervous systems.
Founded in 2011, Trevi Therapeutics is headquartered
in New Haven, CT.
About Haduvio
Haduvio, an investigational therapy, is an oral extended-release
(ER) formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid
receptor agonist and µ-opioid receptor antagonist that has been
approved and marketed as an injectable for pain indications for
more than 20 years in the United States and Europe.
The ĸ- and µ-opioid receptors are known to be critical mediators of
itch, cough and certain movement disorders. Nalbuphine's mechanism
of action may also mitigate the risk of abuse associated with
µ-opioid agonists because it antagonizes, or blocks, µ-opioid
receptors. Parenteral nalbuphine is not currently scheduled as a
controlled substance by the DEA in the United States or
by regulatory authorities in most
of Europe. Trevi intends to propose Haduvio as the
trade name for nalbuphine ER. Nalbuphine ER has been granted Fast
Track designation by the FDA for the proposed indication of
reduction of moderate to severe pruritus in adults with prurigo
nodularis. Its safety and efficacy have not been evaluated by any
regulatory authority.
Investor Contact
Katie
McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia
Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-present-and-participate-in-partnership-meetings-at-upcoming-2022-bio-international-convention-301562512.html
SOURCE Trevi Therapeutics, Inc.